Skip to content

Endoscopic Frontal Sinus Surgery Draf III in Moderate to Severe Eosinophilic Chronic Rhinosinusitis With Polyps

Clinical Evaluation of Primary Endoscopic Frontal Sinus Surgery Grade 6 (Draf III) in Patients With Moderate to Severe Eosinophilic Chronic Rhinosinusitis With Polyps

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05979662
Enrollment
50
Registered
2023-08-07
Start date
2021-01-01
Completion date
2023-09-30
Last updated
2023-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Rhinosinusitis With Nasal Polyps, Draf III, Draf I or IIa, Endoscopic Frontal Sinus Surgery

Brief summary

The aim of this study is to evaluate the effect of the primary endoscopic frontal sinus surgery on the clinical outcome in patients having moderate to severe eosinophilic chronic rhinosinusitis with polyps with primary outcome measures in form of recurrence of polyp using endoscopic polyp score and Secondary outcome measures include Lund MacKay score, SNOT-22 and need for corticosteroid to control polyp postoperatively.

Detailed description

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a common inflammatory disorder, affecting about 4% of the population worldwide and strongly impacts the quality of life of affected patient. Eosinophilic chronic rhinosinusitis (ECRS) is a subtype of recalcitrant Chronic rhinosinusitis . Patients with ECRS and generally having a tissue eosinophil \>10 cells per high power field (HPF), have worse disease severity and poorer treatment outcomes compared to non-Eosinophilic chronic rhinosinusitis.

Interventions

PROCEDUREEndoscopic frontal sinus surgery grade 6(Draf III).

Patients will receive endoscopic frontal sinus surgery grade 6(Draf III).

PROCEDUREEndoscopic frontal sinus surgery grade 1-3(Draf I or IIa)

Patients will receive endoscopic frontal sinus surgery grade 1-3(Draf I or IIa).

Sponsors

Ibrahim Talal Elshamy
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

• Patients with moderate or severe eosinophilic chronic rhinosinusitis with polyps who failed appropriate medical treatment in the form of antibiotic, systemic and local corticosteroid for 3 months .

Exclusion criteria

* Narrow anteroposterior diameter of frontal sinus ostium(1cm or less) * Patients showing less or highest degree of radiological complexity of surgery on studying the Computed Tomography. * Any contraindication for general anesthesia. * Patients below age of 18 years. * Incomplete follow up * previous sinus surgery

Design outcomes

Primary

MeasureTime frameDescription
Recurrence of polyp using endoscopic polyp scoreOne year postoperativelyPolyps were evaluated on each side through nasal endoscopy at each visit and graded based on polyp size, resulting in scores of 0 to 4 9. Zero is no polyp, 1 = small polyps in the middle meatus not reaching below the inferior border of the middle turbinate, 2 = polyps reaching below the lower border of the middle turbinate, 3 = large polyps reaching the lower border of the inferior turbinate or polyps medial to the middle turbinate, and 4 = large polyps causing complete obstruction of the inferior nasal cavity. The sum of the left and right nostril scores is the Nasal Polyp Score

Secondary

MeasureTime frameDescription
Lund MacKay scoreOne year postoperativelyThe Lund-Mackay staging system scores each sinus (anterior ethmoid, posterior ethmoid, maxillary, frontal, and sphenoid sinuses) according to the following scale: 0 (no opacification), 1 (partial opacification), or 2 (complete opacification).
Sinonasal Outcome Test- 22One year postoperativelySNOT- 22 was measured based on a 0-5 scale, where 0 defines no problems with the given symptom and 5 defines maximal problems

Countries

Egypt

Contacts

Primary ContactIbrahim T Elshamy, MSc
hematalal93@gmail.com+20 102 237 3920

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026